Experienced Leadership 

---

Rocky Ganske

President & CEO

​Mr. Ganske brings over 3 decades of both public and private company experience in the medical devices, diagnostics, and life science fields, and has a broad background in management, operations, science and regulatory; blended with the disciplines of corporate processes, and successful entrepreneurial business ventures. Mr. Ganske has personally led multiple business and IP transactions with both Fortune 100 and Fortune 500 companies. He led CellAegis Devices Inc. as the CEO for the last 10 years transitioned the technology out of Sick Kids Hospital, Toronto into a commercial product with CE Mark and Health Canada approval used in several multinational controlled trials, in cardiovascular, stroke, and kidney reperfusion damage.
 
Prior to CDI, Mr. Ganske served as CEO of Axela, a university diagnostics startup focused on real-time proteomic analysis utilizing proprietary diffractive optics technology. Mr. Ganske transitioned Axela to a full operating company, installing Axela’s commercial platform in premier institutes in the US, EU and Asia Pacific. Mr. Ganske was instrumental in negotiating and closing significant patent in-licensing transaction with Fortune 100 companies for over 150 patents and applications and oversaw Axela’s acquisition of Xceed Molecular, a genomics diagnostic company.

Contact: rocky@illumisonics.com
 

---

Paul Weber​
​

Advisor to the CEO

​Mr. Weber is an experienced medtech executive and entrepreneur who brings extensive marketing, commercialization and international business development experience with both large multinational and growth stage medical and technology companies. Prior to joining illumiSonics, Mr. Weber was founder and CEO of Perimeter Medical Imaging.  Perimeter pioneered the use of OCT for use in the in-surgical assessment of tissue microstructures. Prior to founding Perimeter, he led Strategic Business Development and Marketing for Covalon Technologies. In this capacity he helped to transition the company from a technology focus to a commercially focused organization, building out OEM, domestic and international distribution channels. At Sentinelle he led Business Development and Marketing, growing the company from start-up revenues to greater than $18 million in sales in 2 ½ years. After being acquired by Hologic Inc. for $105 million, Mr. Weber led Marketing, integration, and OEM and International Distribution relationships. Mr. Weber has also had leadership roles in business development and product management capacities with Johnson and Johnson, Christie Digital and has consulted for numerous technology start-ups on growth strategies. He has developed and taught MBA courses in Marketing and Commercialization of Technology at Wilfrid Laurier University.

Contact: 
​paul@illumisonics.com

Dr. John Mackey, MD.​​

Chief Medical Officer

​Dr. Mackey, is a medical oncologist and Director of the Clinical Trials Unit at the Cross Cancer Institute in Edmonton, Canada, and a Professor of Oncology at the University of Alberta. In addition to acting as director and lead clinical advisor to illumiSonics, Dr Mackey brings deep medtech commercialization experience.  He co-founded Pacylex Pharmaceuticals, J2 Endeavours, and SMHeartCard Inc.  As Chair of the Alberta Pre-Phase I Program steering committee, he has a highly skilled team committed to bringing new anticancer therapies into clinical testing (www.prephaseone.com). Dr. Mackey has authored or co-authored more than 300 biomedical peer reviewed publications. ​
​
Contact: john.mackey@illumisonics.com

Dr. Parsin Haji Reza, PhD.

Founder & CTO

Dr. Reza discovered and pioneered the PARS® imaging techniques.  In November 2014, he co-founded illumiSonics inc., holding the position of CEO from November 2014 to March 2018.  Dr. Reza is an award winning Assistant Professor at the University of Waterloo and leads a team of optical imaging experts at PhotoMedicine Labs.  He brings more than 10 years experience in optics and biomedical engineering, and continues to advance the validation of PARS® through these efforts and currently  has 35+ peer reviewed journal papers in optics and biomedical Engineering.  He has been recognized for his innovative scientific contributions to advancing the state of optical imaging. 

Contact: parsin@illumisonics.com
https://www.photomedicinelabs.com/

The board

OUR PARTNERS